{
  "paper_metadata": {
    "pmid": "30266954",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted information on BRCA2 variants, including clinical significance, penetrance data, and individual records."
  },
  "variants": [
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.5517_5518delA",
      "protein_notation": null,
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 1,
        "demographics": "Chemo-naive",
        "phenotype": "Platinum resistant"
      },
      "penetrance_data": {
        "total_carriers_observed": 1,
        "affected_count": 0,
        "unaffected_count": 1,
        "uncertain_count": null,
        "penetrance_percentage": 0.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "Case 1",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": null,
          "affected_status": "unaffected",
          "phenotype_details": "Platinum resistant",
          "evidence_sentence": "The chemo-naive BRCA2 mutant PDX #13 had a statistically significant response to both 300 and 450 mg kg\u22121 rucaparib, with median TTH of 81 days for rucaparib 300 mg kg\u22121 vs. 43 days for vehicle (p = 0.01, log-rank test, n = 9, 22), although regressions were not observed."
        }
      ],
      "functional_data": {
        "summary": "The variant is associated with resistance to PARPi.",
        "assays": []
      },
      "segregation_data": null,
      "population_frequency": null,
      "evidence_level": "strong",
      "source_location": "Table 1, Row 3",
      "additional_notes": "The variant was found in a patient-derived xenograft model.",
      "key_quotes": [
        "The chemo-naive BRCA2 mutant PDX #13 had a statistically significant response to both 300 and 450 mg kg\u22121 rucaparib."
      ]
    },
    {
      "gene_symbol": "BRCA2",
      "cdna_notation": "c.2323_2323delT",
      "protein_notation": null,
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 1,
        "demographics": "Chemo-naive",
        "phenotype": "Platinum sensitive"
      },
      "penetrance_data": {
        "total_carriers_observed": 1,
        "affected_count": 1,
        "unaffected_count": 0,
        "uncertain_count": null,
        "penetrance_percentage": 100.0,
        "age_dependent_penetrance": []
      },
      "individual_records": [
        {
          "individual_id": "Case 2",
          "age_at_evaluation": null,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": null,
          "affected_status": "affected",
          "phenotype_details": "Platinum sensitive",
          "evidence_sentence": "BRCA2:c.2323_2323delT22SensitiveCR>120>120<0.001"
        }
      ],
      "functional_data": {
        "summary": "The variant is associated with sensitivity to PARPi.",
        "assays": []
      },
      "segregation_data": null,
      "population_frequency": null,
      "evidence_level": "strong",
      "source_location": "Table 1, Row 4",
      "additional_notes": "The variant was found in a patient-derived xenograft model.",
      "key_quotes": [
        "BRCA2:c.2323_2323delT22SensitiveCR>120>120<0.001"
      ]
    }
  ],
  "tables_processed": [
    {
      "table_name": "Table 1",
      "table_caption": "Responses observed in 12 HGSOC PDX to cisplatin and rucaparib treatment in vivo",
      "variants_extracted": 2
    }
  ],
  "extraction_metadata": {
    "total_variants_found": 2,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "All relevant data for BRCA2 variants were extracted successfully."
  }
}